COVID-19: First part of phase-1 of Covaxin human trial concluded with encouraging results

Published On 2020-07-27 06:50 GMT   |   Update On 2020-07-27 06:50 GMT
Advertisement

Rohtak: The first part of phase-1 of Covaxin human trial completed on Saturday at Post-Graduate Institute (PGI) of Medical Sciences, Rohtak, said Dr Savita Verma, principal investigator of the vaccine trial team.

Speaking to ANI, Dr Verma said that six people were administered the vaccine on Saturday under the second part of phase-1.
"First part of phase-1 of vaccine trial (Covaxin) has been completed. 50 people across India were administered the vaccine and the results were encouraging. Six people were administered vaccine on Saturday under the second part of phase-1," she said.
Advertisement
Human trials of Covaxin, India's first vaccine candidate against coronavirus, began at PGI Rohtak on July 17. Three volunteers were administered Covaxin on that day.

Tags:    
Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News